Regorafenib approved in Metastatic Colorectal cancer;Régorafénib et autorisation de mise sur le marché dans le cancer colorectal métastatique avancé

Bulletin du Cancer

Volumn 100, Issue 10, 2013, Pages 1027-1029

  André, Thierry ^a,b   Dumont, Sarah N ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Anti angioenic; Colorectal cancer; Multi kinase inhibitor; Regorafenib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; REGORAFENIB;

ANGIOGENESIS; ARTICLE; ASTHENIA; CANCER PATIENT; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RASH; TUMOR MICROENVIRONMENT; WILD TYPE;

EID: 84886843264     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1808     Document Type: Article

References (5)

1. Rapport INCa « La situation du Cancer en France en 2011 » - http://www.ecancer.fr/component/docman/doc-download/7708-lasituation- du-cancer-en-france-en-2011
2. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of régorafénib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 2012; 18: 2658-67.
3. Strumberg D, Scheulen ME, Schultheis B, et al. Régorafénib (BAY 73-4506) in advanced colorectal cancer: a phase I study. British journal of cancer 2012; 106: 1722-7.
4. Grothey A, Cutsem EV, Sobrero A, et al. For the CORRECT Study Group. Régorafénib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
5. André T, Raymond E, de Gramont A. Correspondance. Is there room for optimizing régorafénib in metastatic colorectal cancer and advanced gastrointestinal stromal tumors? Lancet 2013; 381: 1536-7.